NAOS SIGNED

Project "NAOS" data sheet

The following table provides information about the project.

 Partnership

Take a look of project's partnership.

Map

 Project objective

The objective of this innovation project is to develop a disruptive implantable neurostimulator for the treatment of epilepsy with the goal to place it on the market by 2021.

Neurostimulation is a $4.7 billion market and one of the fastest-growing areas of medicine, that has been approved for the treatment of several neurological disorders. Among these, epilepsy is the most frequent nervous system disease. Of the 50 million people suffering from epilepsy, with 3.7 million in Europe, approximately one third of them are resistant to medication but respond well to the neurostimulation.

Neurostimulators are small implanted devices stimulating nerves or brain tissue. The innovative aspects of the project are based on a Synergia Medical’s patented concept and consists in replacing wires by optical fibres.

The innovation will improve the traditional therapy and brings the main following competitive advantages: - it renders the neurostimulator compatible with magnetic resonance imaging (MRI) diagnosis - it provides a highly tunable stimulation and ultra low power consumption - it improves safety due to electrical isolation and allow for a smaller size implant

The main objective of this feasibility study is to complete the business plan by: - completing a market study and refining specifications of the neurostimulator with key opinion leaders in the field of epilepsy; - manufacturing prototypes of neurostimulators to validate stimulation capabilities, low power consumption, compactness, optical chain efficiency and estimate production costs; - refining the development and production planning, including budget and human resources, based on cost estimates and test results; - finalizing the selection of subcontractors involved in the production chain; - filing additional patents and realizing a complete FTO.